Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2018 Q2- Text added to 2018 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
American, antitumor, AUGMENTTM, Baran, BELIEVETM, Blueprint, breast, diagnosed, embedded, enasidenib, endpoint, EORTC, exert, fiduciary, Fisher, formulation, Gerold, glioblastoma, Heritage, marizomib, MEDALISTTM, metabolic, misleading, moderate, moot, Natco, NDA, Organisation, oversight, placebo, President, proper, RADIANCETM, REVLIMID®ANTITRUST, rituximab, Sam, showed, statistically, STYLETM, Sun, SUNBEAMTM, Susan, THALOMID®AND, unjustly, VAT, waste
Removed:
accretion, flat, reevaluate, Targeted
Valuein 2018 Q2 filing- Value in 2018 Q3 filing
Original filings
Filing view